Vnitr Lek 2024, 70(1):49-54 | DOI: 10.36290/vnl.2024.009

News in insulin treatment

Dominika Mačáková, Ondřej Krystyník, Ľubica Cibičková, David Karásek
III. interní klinika - nefrologická, endokrinologická a revmatologická, LF UP a Fakultní nemocnice Olomouc

Although more than 100 years have passed since the discovery of insulin, this body's own hormone and drug is still widely used in the treatment od diabetes. With the help of modern procedures we try to adapt its administration to the physiological state as much as possible. The changed pharmacokinetics of rapid-acting insulin analogs, which closely copies the physiological curve of insulin release after food intake, helps us. And we also add prolonged effect of basal insulin analogs and theirs flatter pharmacokinetic profile. Thanks to these modifications, we are able to individualize the treatment of diabetes, archieve better compensation and lower the risk of late diabetic complications.

Keywords: insulin, insulin analogs, type 1 diabetes mellitus, type 2 diabetes mellitus.

Accepted: February 9, 2024; Published: February 26, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mačáková D, Krystyník O, Cibičková Ľ, Karásek D. News in insulin treatment. Vnitr Lek. 2024;70(1):49-54. doi: 10.36290/vnl.2024.009.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Semlitsch T, Engler J, Siebenhofer A, et al. (Ultra-) long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4. PMID: Go to original source... Go to PubMed...
    2. Dong ZY, Feng JH, Zhang JF. Efficacy and Tolerability of Insulin Degludec Versus Other Long-acting Basal Insulin Analogues in the Treatment of Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis. Clin Ther. 2022 Nov;44(11):1520-1533. doi: 10.1016/j.clinthera.2022.09.012. Epub 2022 Oct 28. PMID: 36763996. Go to original source... Go to PubMed...
    3. Zhou Z, Sun B, Huang S, et al. Glycemic Variability: Adverse Clinical Outcomes and How to Improve It? Cardiovasc Diabetol. 2020;19:102. doi: 10.1186/s12933-020-01085-6 Go to original source... Go to PubMed...
    4. Yang Y, Long C, Li T, et al. Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Endocrinol (Lausanne). 2022 May 26;13:890090. doi: 10.3389/fendo.2022.890090. PMID: 35721710; PMCID: PMC9204495 Go to original source... Go to PubMed...
    5. Nishimura E, Pridal L, Glendorf T, et al. Molecular and pharmacological characterization of insulin icodec: A new basal insulin analog designed for once-weekly dosing. BMJ Open Diabetes Res Care. 2021;9:e002301. doi: 10.1136/bmjdrc-2021-002301. Go to original source... Go to PubMed...
    6. Philis-Tsimikas A, Bajaj HS, Begtrup K, et al. Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes. Diabetes Obes Metab. 2022;25:331-41. doi: 10.1111/dom.14871 Go to original source... Go to PubMed...
    7. Heise T, Chien J, Beals JM, et al. Pharmacokinetic and pharmacodynamic properties of the novel basal insulin fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. Diabetes Obes Metab 2023;25:1080-90 Go to original source... Go to PubMed...
    8. Howey DC, Bowsher RR, Brunelle RL, et al. (Lys(B28), Pro(B29))-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994;43:396-402. Go to original source...
    9. Fullerton B, Siebenhofer A, Jeitler K, et al. Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2018 Dec 17;12(12):CD013228. doi: 10.1002/14651858.CD013228. PMID: 30556900; PMCID: PMC6517032. Go to original source... Go to PubMed...
    10. Fullerton B, Siebenhofer A, Jeitler K, et al. Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus. Cochrane Database Syst Rev. 2016 Jun 30;2016(6):CD012161. doi: 10.1002/14651858.CD012161. PMID: 27362975; Go to original source... Go to PubMed...
    11. Nicolucci A, Ceriello A, Di Bartolo, et al. Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes. Diabetes Ther. 2020 Mar;11(3):573-584. doi: 10.1007/s13300-019-00732-w. Epub 2019 Dec 23. PMID: 31873857; PMCID: PMC7048883. Go to original source... Go to PubMed...
    12. Heise T, Hövelmann U, Brøndsted L, et al. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab2015;17:682-688 Go to original source... Go to PubMed...
    13. Mathieu C, Bode BW, Franek E, et al. Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): a 52-week, randomized, treat-to-target, phase III trial. Diabetes Obes Metab2018;20:1148-1155 Go to original source... Go to PubMed...
    14. Pratt E, Leohr J, Heilmann C, et al. Treprostinil causes local vasodilation, is well tolerated, and results in faster absorption of insulin lispro [Abstract]. Diabetes2017;66(Suppl. 1):A253
    15. Michael MD, Zhang C, Siesky AM, et al. Exploration of the mechanism of accelerated absorption for a novel insulin lispro formulation. Diabetes 2017;66(Suppl. 1):A250
    16. Blevins T, Zhang Q, Frias JP, et al. Randomized double-blind clinical trial comparing ultra rapid lispro with lispro in a basal-bolus regimen in patients with type 2 diabetes: PRONTO-T2D. Diabetes Care 2020;43:2991-2998 Go to original source... Go to PubMed...
    17. Giugliano D, Chiodini P, Maiorino MI, et al. Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Endocrine. 2016;51:417-428. doi: 10.1007/s12020-015-0718-3. Go to original source... Go to PubMed...
    18. Wang H, Zhou Y, Wang Y, et al. Basal Insulin Reduces Glucose Variability and Hypoglycaemia Compared to Premixed Insulin in Type 2 Diabetes Patients: A Study Based on Continuous Glucose Monitoring Systems. Front Endocrinol (Lausanne). 2022 Apr 27;13:791439. doi: 10.3389/fendo.2022.791439. PMID: 35574003; PMCID: PMC9092280. Go to original source... Go to PubMed...
    19. Visolyi GÁ, Domján BA, Svébis MM, et al. Comparison of Efficacy and Safety of Commercially Available Fixed-Ratio Combinations of Insulin Degludec/Liraglutide and Insulin Glargine/Lixisenatide: A Network Meta-analysis. Can J Diabetes. 2023 Jun;47(4):368-377. doi: Go to original source... Go to PubMed...
    20. Šumnîk Z, Prázný M, Pelikánová T, Škrha J. Doporučený postup péče o diabetes 1. typu České diabetologické společnosti ČLS JEP. 2019
    21. Doporučený postup péče o diabetes mellitus 2.typu České diabetologické společnosti ČLS JEP. 2018
    22. Hanefeld M. Use of insulin in type 2 diabetes: what we learned from recent clinical trials on the benefits of early insulin initiation. Diabetes Metab. 2014 Dec;40(6):391-9. doi: 10.1016/j.diabet.2014.08.006. PMID: 25451189. Go to original source... Go to PubMed...
    23. Zhang W, Wang H, Liu F, et al. Effects of Early Intensive Insulin Therapy on Endothelial Progenitor Cells in Patients with Newly Diagnosed Type 2 Diabetes. Diabetes Ther. 2022 Apr;13(4):679-690. doi: 10.1007/s13300-021-01185-w. Epub 2021 Dec 11. Erratum in: Diabetes Ther. 2022 Mar 14; PMID: 34894328; PMCID: PMC8991286. Go to original source... Go to PubMed...
    24. Stojanovic J, Andjelic-Jelic M, Vuksanovic M, et al. The effects of early short-term insulin treatment vs. glimepiride on beta cell function in newly diagnosed type 2 diabetes with HbA1c above 9. Turk J Med Sci. 2023 Apr;53(2):552-562. doi: 10.55730/1300-0144.5616. Epub 2023 Apr 19. PMID: 37476884; PMCID: PMC10387975. Go to original source... Go to PubMed...
    25. Jeon HL, Kim W, Kim B, et al. Relationship between the early initiation of insulin treatment and diabetic complications in patients newly diagnosed with type 2 diabetes mellitus in Korea: A nationwide cohort study. J Diabetes Investig. 2022 May;13(5):830-838. doi: 10.1111/jdi.13719. Epub 2021 Dec 9. PMID: 34825507; PMCID: PMC9077737. Go to original source... Go to PubMed...
    26. Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367(4):319-328. doi: 10.1056/NEJMoa1203858 Go to original source... Go to PubMed...
    27. GRADE Study Research Group, Nathan DM, Lachin JM, et al. Glycemia reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. N Engl J Med 2022;387:1075. Go to original source... Go to PubMed...
    28. Falcetta P, Nicolì F, Citro F, et al. De-intensification of basal-bolus insulin regimen after initiation of a GLP-1 RA improves glycaemic control and promotes weight loss in subjects with type 2 diabetes. Acta Diabetol 2023;60(1):53-60, doi: 10.1007/s00592-022-01974-0. Go to original source... Go to PubMed...
    29. Billings LK, Doshi A, Gouet D, et al. Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: The DUAL VII randomized clinical trial. Diabetes Care. 2018;41(5):1009-1016, doi: 10.2337/dc17-1114. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.